Efficacy of hepatitis B vaccination and interferon-α-2b combination therapy versus interferon-α-2b monotherapy in children with chronic hepatitis B

Simple item page
dc.contributor.authorHelvaci, M
dc.contributor.authorKizilgunesler, A
dc.contributor.authorKasirga, E
dc.contributor.authorOzbal, E
dc.contributor.authorKuzu, M
dc.contributor.authorSozen, G
dc.date.accessioned2024-07-18T11:53:49Z
dc.date.available2024-07-18T11:53:49Z
dc.description.abstractBackground: Although interferon (IFN) has been approved in the treatment of chronic hepatitis B in children, it is effective only in 30-40% of patients. In some studies it has been suggested that therapeutic use of anti-hepatitis B virus (HBV) vaccine may be beneficial in patients with chronic hepatitis B. The aim of the present study was to compare the efficacy of hepatitis B vaccination and IFN-alpha-2b in combination and IFN-alpha-2b monotherapy in children with chronic hepatitis B. Methods: Fifty treatment-naive children with chronic hepatitis B infection were randomly assigned to receive either 5 million units/m(2) recombinant IFN-alpha-2b subcutaneously three times per week for 9 months, and pre-S2/S vaccine at the beginning and 4 and 24 weeks after initiation of IFN therapy (n = 25) or recombinant IFN-alpha-2b (5 million units/m(2) subcutaneously thrice weekly) alone for 9 months (n = 25). Children were followed for at least 6 months after the end of therapy. Results: There was no statistically significant difference in the mean alanine aminotransferase levels, histologic activity index and fibrosis scores between combination and IFN monotherapy groups at the end of the therapy and end of the follow-up period. When combination and monotherapy groups were compared, the mean HBV-DNA values were significantly reduced in combination group at the end of the therapy (P = 0.004), but no statistically significant difference was found at the end of the follow up. Sustained HBeAg seroconversion with clearance of HBV-DNA was obtained in 13 of 25 children (52%) treated with combination therapy, and in eight of 25 patients (32%) treated with IFN monotherapy (P = 0.251). Conclusion: Although the difference was statistically insignificant, the sustained response rates were better in the combination therapy group than in the monotherapy group. The potential benefit of combining IFN and hepatitis B vaccine should be investigated in further studies with different regimens of combination therapy. (C) 2004 Blackwell Publishing Asia Pty Ltd.
dc.identifier.issn0815-9319
dc.identifier.other1440-1746
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/5883
dc.language.isoEnglish
dc.publisherWILEY
dc.subjectIMMUNOTOLERANT PHASE
dc.subjectIMMUNOTHERAPY
dc.subjectINFECTION
dc.subjectMANAGEMENT
dc.subjectRESPONSES
dc.subjectANTIGENS
dc.subjectALPHA
dc.titleEfficacy of hepatitis B vaccination and interferon-α-2b combination therapy versus interferon-α-2b monotherapy in children with chronic hepatitis B
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu